JP2017519989A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519989A5 JP2017519989A5 JP2016573763A JP2016573763A JP2017519989A5 JP 2017519989 A5 JP2017519989 A5 JP 2017519989A5 JP 2016573763 A JP2016573763 A JP 2016573763A JP 2016573763 A JP2016573763 A JP 2016573763A JP 2017519989 A5 JP2017519989 A5 JP 2017519989A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- ceramide
- alkyl chain
- formula
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940106189 ceramide Drugs 0.000 claims 78
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 77
- 125000000217 alkyl group Chemical group 0.000 claims 76
- 125000004432 carbon atom Chemical group C* 0.000 claims 76
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 74
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 74
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 74
- 238000000034 method Methods 0.000 claims 28
- 239000012472 biological sample Substances 0.000 claims 25
- 239000000523 sample Substances 0.000 claims 23
- 239000013068 control sample Substances 0.000 claims 14
- 230000002526 effect on cardiovascular system Effects 0.000 claims 10
- 229920006395 saturated elastomer Polymers 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 102000004895 Lipoproteins Human genes 0.000 claims 6
- 108090001030 Lipoproteins Proteins 0.000 claims 6
- 210000004369 blood Anatomy 0.000 claims 6
- 239000008280 blood Substances 0.000 claims 6
- 210000002966 serum Anatomy 0.000 claims 6
- 150000001783 ceramides Chemical class 0.000 claims 4
- ZJVVOYPTFQEGPH-UHFFFAOYSA-N 102917-80-6 Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)NC(CO)C(O)C=CCCCCCCCCCCCCC ZJVVOYPTFQEGPH-UHFFFAOYSA-N 0.000 claims 3
- YDNKGFDKKRUKPY-TURZORIXSA-N N-hexadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC YDNKGFDKKRUKPY-TURZORIXSA-N 0.000 claims 3
- VODZWWMEJITOND-NXCSZAMKSA-N N-octadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC VODZWWMEJITOND-NXCSZAMKSA-N 0.000 claims 3
- ZJVVOYPTFQEGPH-AUTSUKAISA-N N-tetracosanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC ZJVVOYPTFQEGPH-AUTSUKAISA-N 0.000 claims 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 2
- 206010000891 acute myocardial infarction Diseases 0.000 claims 2
- 229910052805 deuterium Inorganic materials 0.000 claims 2
- 238000004949 mass spectrometry Methods 0.000 claims 2
- 239000013589 supplement Substances 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 238000012421 spiking Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462012543P | 2014-06-16 | 2014-06-16 | |
| US62/012,543 | 2014-06-16 | ||
| US14/677,595 | 2015-04-02 | ||
| US14/677,595 US9347960B2 (en) | 2014-06-16 | 2015-04-02 | Ceramides and their use in diagnosing CVD |
| PCT/EP2015/063492 WO2015193325A2 (en) | 2014-06-16 | 2015-06-16 | Ceramides and their use in diagnosing cvd |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519989A JP2017519989A (ja) | 2017-07-20 |
| JP2017519989A5 true JP2017519989A5 (enExample) | 2018-07-26 |
| JP6774879B2 JP6774879B2 (ja) | 2020-10-28 |
Family
ID=54835950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016573763A Active JP6774879B2 (ja) | 2014-06-16 | 2015-06-16 | セラミド及びｃｖｄ診断におけるその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US9347960B2 (enExample) |
| EP (2) | EP3155440B1 (enExample) |
| JP (1) | JP6774879B2 (enExample) |
| KR (3) | KR102636885B1 (enExample) |
| CN (1) | CN106461685B (enExample) |
| CA (1) | CA2951578A1 (enExample) |
| MX (1) | MX380642B (enExample) |
| SA (1) | SA516380503B1 (enExample) |
| SG (1) | SG11201609621RA (enExample) |
| WO (1) | WO2015193325A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9347960B2 (en) * | 2014-06-16 | 2016-05-24 | Zora Biosciences, Oy | Ceramides and their use in diagnosing CVD |
| WO2016100549A2 (en) * | 2014-12-16 | 2016-06-23 | Washington University | Ceramides for evaluating risk of cardiovascular disease |
| EP3714273A1 (en) * | 2017-11-20 | 2020-09-30 | Zora Biosciences OY | Methods for prediction and early detection of diabetes |
| CN108037275A (zh) * | 2017-12-14 | 2018-05-15 | 北京豪思生物科技有限公司 | 一种用于评估冠状动脉疾病的试剂盒 |
| WO2020112149A1 (en) * | 2018-12-01 | 2020-06-04 | Binhai Industrial Technology Research Institute Of Zhejiang University | Methods and compositions for the assessment of acute myocardial infarction (ami) |
| US12399188B2 (en) | 2018-12-06 | 2025-08-26 | Zora Biosciences Oy | Biomarkers for cardiovascular events |
| CN112730638B (zh) * | 2020-11-25 | 2022-07-29 | 首都医科大学附属北京朝阳医院 | 糖尿病合并心梗代谢标志物、检测试剂及试剂盒 |
| CN112986454A (zh) * | 2021-05-18 | 2021-06-18 | 天津云检医疗器械有限公司 | 急性心肌梗死的血清标志物、试剂盒和用途 |
| CN113495160B (zh) * | 2021-09-07 | 2021-11-19 | 宝枫生物科技（北京）有限公司 | 用于诊断高原环境下的缺血缺氧性脑病补充神经酸起效的分子标志物及其应用 |
| WO2023108294A1 (en) * | 2021-12-17 | 2023-06-22 | National Research Council Of Canada | Diagnostic lipid biomarkers for covid-19 and methods for use thereof |
| CN116500179B (zh) * | 2023-04-21 | 2023-12-26 | 南京品生医疗科技有限公司 | 一种血浆中神经酰胺相关因子的原始得分计算及转换方法和系统 |
| CN119198939B (zh) * | 2024-08-30 | 2025-06-03 | 北京大学第三医院（北京大学第三临床医学院） | 神经酰胺的检测试剂盒、应用检测试剂盒检测神经酰胺的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2529235B1 (en) | 2010-01-29 | 2019-03-06 | Metanomics GmbH | Means and methods for diagnosing heart failure in a subject |
| NO2385374T3 (enExample) | 2010-05-05 | 2014-06-07 | ||
| CN108445241B (zh) * | 2010-06-20 | 2021-11-02 | 佐拉生物科学公司 | 用于鉴定高风险冠状动脉疾病患者的脂质组学标志 |
| US9541565B2 (en) | 2011-04-08 | 2017-01-10 | Zora Biosciences Oy | Biomarkers for sensitive detection of statin-induced muscle toxicity |
| EP3190418B1 (en) | 2011-07-28 | 2019-05-01 | metanomics GmbH | Use of sm_sphingomyelin (d18:1, c16:0) as a marker for heart failure |
| EP2592422A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment |
| EP2592423A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
| US20160047829A1 (en) | 2012-10-18 | 2016-02-18 | Ruprecht-Karls-Universität Heidelberg | Means and Methods for Determining a Clearance Normalized Amount of a Metabolite Disease Biomarker in a Sample |
| CA2903946A1 (en) | 2013-03-08 | 2014-09-12 | Zora Biosciences Oy | Non-high density lipoprotein derived cvd markers |
| US9347960B2 (en) * | 2014-06-16 | 2016-05-24 | Zora Biosciences, Oy | Ceramides and their use in diagnosing CVD |
-
2015
- 2015-04-02 US US14/677,595 patent/US9347960B2/en active Active
- 2015-06-16 CA CA2951578A patent/CA2951578A1/en not_active Abandoned
- 2015-06-16 MX MX2016016742A patent/MX380642B/es unknown
- 2015-06-16 CN CN201580031908.1A patent/CN106461685B/zh active Active
- 2015-06-16 JP JP2016573763A patent/JP6774879B2/ja active Active
- 2015-06-16 SG SG11201609621RA patent/SG11201609621RA/en unknown
- 2015-06-16 EP EP15733650.4A patent/EP3155440B1/en active Active
- 2015-06-16 KR KR1020177000864A patent/KR102636885B1/ko active Active
- 2015-06-16 WO PCT/EP2015/063492 patent/WO2015193325A2/en not_active Ceased
- 2015-06-16 KR KR1020257030977A patent/KR20250139419A/ko active Pending
- 2015-06-16 KR KR1020247004744A patent/KR102864779B1/ko active Active
- 2015-06-16 EP EP22168767.6A patent/EP4089416A1/en active Pending
-
2016
- 2016-05-19 US US15/159,650 patent/US10197582B2/en active Active
- 2016-12-15 SA SA516380503A patent/SA516380503B1/ar unknown
-
2018
- 2018-12-12 US US16/218,363 patent/US11474116B2/en active Active
-
2022
- 2022-02-10 US US17/668,927 patent/US11940453B2/en active Active
-
2024
- 2024-02-14 US US18/441,255 patent/US20240183866A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519989A5 (enExample) | ||
| Gould et al. | Breath analysis for detection of viral infection, the current position of the field | |
| Azab et al. | Robust method for high-throughput screening of fatty acids by multisegment injection-nonaqueous capillary electrophoresis–mass spectrometry with stringent quality control | |
| Jung et al. | High throughput quantitative molecular lipidomics | |
| Spalding et al. | Trace phosphate improves ZIC-pHILIC peak shape, sensitivity, and coverage for untargeted metabolomics | |
| KR102864779B1 (ko) | 세라마이드 및 이의 관상동맥질환 진단 용도 | |
| Agnello et al. | Establishing the upper reference limit of Galectin-3 in healthy blood donors | |
| JP2014508298A5 (enExample) | ||
| RU2015136673A (ru) | Биомаркеры сахарного диабета 2 типа и их применение | |
| GB2495163B (en) | Real-time compositional analysis of hydrocarbon based fluid samples | |
| JP2012529010A5 (enExample) | ||
| JP7578125B2 (ja) | 試料の評価方法、分析方法、劣化試料の検出方法、劣化血漿試料検出用マーカーおよび劣化血清試料検出用マーカー | |
| JP2014517313A5 (enExample) | ||
| JP2013527437A5 (enExample) | ||
| JP2018529931A5 (enExample) | ||
| Cabruja et al. | In-depth triacylglycerol profiling using MS3 Q-Trap mass spectrometry | |
| WO2013166444A3 (en) | Biomarker analysis using scodaphoresis | |
| Dahlfors et al. | Validation of a competitive ELISA assay for the quantification of human serum hepcidin | |
| JP2015500464A5 (enExample) | ||
| JP6998023B2 (ja) | 非アルコール性脂肪肝疾患の検出方法、非アルコール性脂肪肝疾患検出用キットおよび非アルコール性脂肪肝疾患検出用バイオマーカー | |
| Herath et al. | Determination of low levels of 2H‐labeling using high‐resolution mass spectrometry: Application in studies of lipid flux and beyond | |
| Tyan et al. | Utilizing isotope dilution-matrix-assisted laser desorption ionization-time of flight mass spectrometry as a reference procedure for the radioimmunoassay of serum thyroxine | |
| JP4811467B2 (ja) | 質量分析データ解析方法及び装置 | |
| Fernandez Peralbo et al. | Targeted analysis of omega‐6‐derived eicosanoids in human serum by SPE‐LC‐MS/MS for evaluation of coronary artery disease | |
| CN104614212B (zh) | 一种贴壁细胞定量代谢组学分析样品预处理的方法 |